The purpose of this study was to compare an experimental regimen of atovaquone plus proguanil with the standard regimen of quinine plus tetracycline for the treatment of uncomplicated falciparum malaria. The study was designed as an open, randomized study of men presenting with symptoms of uncomplicated malaria and thick-smear slide confirmation of parasitemia (1000 -100,000 ring forms/mL). Subjects were hospitalized for 28 days to insure medication compliance and to rule out the possibility of reinfections. With 77 patients in each group, the cure rates were 98.7% and 100% for atovaquone plus proguanil and quinine plus tetracycline, respectively. The parasite clearance times (mean, 56 h) and fever clearance times (mean, 19 h) were significantly shorter in the atovaquone plus proguanil group, and there were significantly fewer side effects in the atovaquone plus proguanil group. Atovaquone plus proguanil is an efficacious, easily administered, safe regimen for the treatment of uncomplicated, multidrug-resistant falciparum malaria in Brazil.
Multidrug-resistant falciparum malaria continues to be a madisseminate resistant strains throughout the region. During the past decades, parasite drug resistance to chloroquine, pyrimethjor public health problem in developing countries, requiring new treatment regimens nearly every decade. The problem is amine-sulfadoxine, and to some extent, quinine [2] has developed at an alarming rate. Currently, the recommended regimens especially severe in Brazil, which has experienced a 3-fold rise for uncomplicated falciparum malaria in order of priority are in malaria during the past decade, to nearly 600,000 infections quinine plus tetracycline for 7 days, quinine alone for 10 days, annually, approximately half of which are falciparum [1] .
and a single dose of mefloquine [3] . The first two regimens Nearly all of the malaria is confined to the Amazon region, in have problems with poor compliance and many side effects. which migrant populations, great distances, and poor access to
Half the patients do not comply for ú3 days (de Alencar FEC, diagnosis and treatment are major obstacles to malaria control. unpublished data). Mefloquine is expensive, and because of its Presumptive treatment without diagnosis has led to overuse of long half-life, resistance may develop rapidly through reinfecantimalarials and is probably a significant factor in the generations in malaria-endemic areas. tion of parasite resistance. Migrant populations can rapidly As in other areas of the world faced with multidrug resistance, the options for alternatives are few and problematic. Increasing the dose of existing regimens may lead to toxicity and only delay the development of resistance. Combining dif-were administered under supervision of the study staff. Blood for indicated only for the treatment of severe malaria because of determining serum drug levels was drawn at 8 and 96 h after the their rapid clinical and parasitologic effects [3] . When used first dose. Patients' temperatures and pulses were checked at 4-h alone for the treatment of uncomplicated malaria, these comintervals during the first week of admission.
pounds produce high recrudescence rates [4] . Another promisThe patients were examined daily for the first week and weekly ing new drug, atovaquone, has shown few side effects, high thereafter. At each examination, signs and symptoms were checked efficacy, easy compliance, and little cross-resistance in prelimiby a standard questionnaire. If any complaint was present, it was nary studies [5] .
checked daily until it disappeared or the patient was discharged.
Atovaquone is a hydroxynaphthoquinone with a structure Blood for slides was obtained at 6-h intervals for thick-smear different from that of other antimalarials, and it has shown parasite counts, until three consecutive slides were negative; counts good activity in vitro and in animals [6] clinical trials against falciparum malaria showed high recrudes-
The level of resistance (levels RI-RIII) was defined according to cence rates [11] . On the basis of a synergistic effect against the WHO criteria for 4-aminoquinolines: RIII, parasite count Plasmodium falciparum in vitro [12] and a long history of safe §25% of the initial parasite count 48 h after initiation of therapy; use, proguanil was added to the atovaquone regimen. Since RII, parasite count õ25% of the initial count at 48 h and parasitemia on day 7; RI, clearance of parasitemia by day 7 but recurthis combination showed high cure rates in Southeast Asia [5] rence before or on day 28.
and because in vitro data suggest that 90% of Brazilian isolates
Drugs and regimens. Atovaquone (1 g) and proguanil (400 are sensitive to proguanil (S. Di Santi, personal communicamg) were given together for 3 days as single daily doses [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] tion), we felt that this combined regimen had promise. The min after a small amount of fatty food. Quinine (600 mg three purpose of our study was to see whether atovaquone plus protimes a day) and tetracycline (250 mg four times a day) were given guanil would be effective against the multidrug-resistant strain concurrently for 7 days.
of P. falciparum in Brazil.
Adverse effects. We considered as possible side effects any sign or symptom not present or worse after admission that was not related to malaria and that had onset close to the time of drug
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administration (Ç1 week after the last dose). Study population. The study was conducted in Peixoto de
Statistical analysis. Baseline data were examined to assess Azevedo (population Ç40,000), a town in the southern Brazilian the comparability of the 2 study groups. Outcome parameters (feAmazon. Peixoto has one of the highest malaria transmission rates ver clearance times, parasite clearance times, cure rates) and in Brazil, Ç300 cases/week (half vivax and half falciparum). The side effects were compared between groups. Statistical tests (x 2 , principal occupations in Peixoto are gold mining, logging, and analysis of variance, nonparametric tests of means, and confidence farming. Adult men (ages 18-65 years) in general good health intervals) were done with Epi Info (version 6.0; USD, Stone Mounpresenting with smear-confirmed falciparum malaria at the Fundatain, GA). ção Nacional de Saúde (National Health Foundation) posts were asked to participate in the study.
Study design. Patients were admitted to the research ward (a Results malaria-free area) of the local hospital for 28 days. Upon admisFrom April 1995 to January 1996, 175 patients were entered sion, slides were repeated to confirm the entry criteria of 1000-100,000 ring forms/mL, patient histories were obtained, and physiinto the study. Of them, 21 were withdrawn because of the cal examinations were done. Specimens were obtained for baseline following reasons: 6 left the ward before day 28, 1 failed to laboratory examination (complete blood cell counts and differentake the study drug for 24 h, 9 were treated with a complete tials, determination of values for serum creatinine, urea, liver enregimen of chloroquine and primaquine before we decided to zymes, bilirubin, albumin, and glucose, and evaluation of urinary use suppressive chloroquine doses, 2 were mistakenly diag- All patients in the quinine plus tetracycline group were extremely difficult. The rapid development of parasite drug resistance has been and will continue to be a serious obstacle cured, and 1 patient had recrudescence in the atovaquone plus proguanil group (RI, positive on day 21), giving a cure to control in this region. The task is even more difficult because not only must new efficacious therapies be discovered, but the rate of 100% (confidence interval [CI] Å 95% -100%) for the quinine plus tetracycline group and 98.7% (CI Å 92% -regimens must also be easy to use and have few side effects since poor compliance will lead to the rapid development of 99%) for the atovaquone plus proguanil group. When we exclude all subjects who developed and were treated (comresistance to the drugs. We have shown that our atovaquone plus proguanil study regimen fulfills all these criteria of high plete or incomplete regimen) for vivax malaria prior to day 28, 72 of the 73 subjects (98.6%, CI Å 92.6% -100%) in efficacy, easy administration, and few side effects. Furthermore, the relatively short half-life minimizes the possibility of the atovaquone plus proguanil group and 69 subjects (100%, CI Å 94.8% -100%) in the quinine plus tetracycline group developing resistance via reinfections occurring when posttherapeutic drug levels are low. were cured. The mean parasite clearance times (mean { SD) were shorter in the atovaquone plus proguanil group (56.1
Regarding new treatments for falciparum malaria, the alternatives are few. Mefloquine, once considered an ideal alterna-{ 14.1 h) than in the quinine plus tetracycline group (64.5 { 23.1 h; P Å .008), as were the fever clearance times for tive because of the ease of administration and the few side effects, has achieved indices of 50% resistance in some areas the 63 atovaquone plus proguanil subjects (18.8 { 17.7 h) and the 56 quinine plus tetracycline subjects (28.5 { 19.8 of Thailand [13] . Perhaps this is due to its cross-resistance with quinine, which was used for long periods prior to the h) who were admitted with fever ( P Å .05).
Forty-eight patients (62.3%) had side effects in the atovaintroduction of mefloquine, or its long half-life in areas with high reinfection rates. Brazilian patients are poorly compliant quone plus proguanil group, compared with 69 (89.6%) in the quinine plus tetracycline group. The most common side effects with quinine and tetracycline regimens because of long, frequent dosing schedules and frequent side effects. This leads to observed were tinnitus, dizziness, abdominal pain, nausea, weakness, headache, diarrhea, anorexia, pruritus, and vomiting.
poor effectiveness, which further exacerbates poor compliance. One of the newer options is the combination of artemisinin There were more patients complaining about tinnitus (55 vs. 3; P õ 0.01), dizziness (39 vs. 10; P õ 0.01), nausea (22 derivatives and slow-acting schizonticides [14] , but this is not yet a well-established alternative. vs. 12; P Å 0.05), and anorexia (13 vs. 5, P Å .04) in the quinine plus tetracycline group than in the atovaquone plus
Regarding the high efficacy rates of atovaquone plus proguanil, our results agree with what has been shown in other areas proguanil group (table 1) . No subjects with normal admission values developed abnormal laboratory values during treatment, of the world [15] . Although the semi-immune status of our subjects may have contributed to their good clinical and parasiexcept for elevated eosinophilia, which we attributed to intestinal parasites. tologic response to both drugs, the high cure rate, shorter fever / 9d2a$$ju22 04-25-97 11:39:14 jinfa UC: J Infect
